Tralokinumab

LEO Pharma announced positive 16-week interim results from the phase 3b ADHAND trial, with tralokinumab meeting all primary and secondary endpoints for moderate to severe atopic dermatitis on the hands.

• Sanofi's amlitelimab (formerly KY1005), acquired through its $1.45 billion Kymab purchase, demonstrated significant efficacy in a Phase 2a trial for moderate to severe atopic dermatitis with an 80% improvement in EASI scores at the low dose. • The OX40 ligand-targeting antibody showed durable effects, with two-thirds of patients maintaining clear or almost clear skin 24 weeks after the final dose, positioning it as a potential complement to Sanofi's blockbuster Dupixent. • Despite increasing competition in the atopic dermatitis market from biologics and JAK inhibitors, Sanofi is advancing amlitelimab to Phase 2b trials, emphasizing the need for diverse treatment options for this challenging condition.

• Ruxolitinib cream demonstrates positive long-term safety profile in atopic dermatitis patients, with lower rates of cutaneous infections compared to untreated populations according to extended clinical trial data. • The JAK inhibitor topical treatment outperforms mid-potency corticosteroids while being suitable for delicate skin areas including the face and body folds, potentially preventing progression to systemic therapy. • Experts emphasize shared decision-making as crucial in atopic dermatitis management, with treatment plans tailored to patient history, disease severity, and consideration of the skin microbiome's role in disease pathogenesis.

The TRACE study revealed that tralokinumab significantly reduced the severity of genital atopic dermatitis (AD) within three months.

• Analysis of 50 countries shows significant disparities in biologic medication access for atopic dermatitis, with high-SDI countries having 28.2 times greater utilization rates than lower-middle/middle-SDI nations. • Global biologic use increased dramatically from 2017 to 2022, expanding from just 3 high-SDI countries to 50 countries, with average utilization rising from 1.1 to 192.9 units per 100,000 individuals. • Research reveals sociodemographic status, rather than disease burden, primarily determines biologic access, highlighting financial barriers in lower-income countries despite medical need.